Sancilio Pharmaceuticals Co. Inc. has filed an S-1 form with the Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No terms were given in the filing, but the offering is valued up to $86.25 million. The company intends to list on the Nasdaq Capital Market under the symbol SPCI.

The underwriters for the offering are UBS, Piper Jaffray, JMP Securities and FBR.

This is a fully integrated specialty pharmaceutical company focused on developing and, in the future, commercializing products based on its proprietary Advanced Lipid Technologies (ALT) platform. Sancilio intends to utilize its current manufacturing facility to manufacture our proprietary product candidates, if approved.

ALT is designed to enhance the bioavailability, reduce the food effect and improve the efficacy of lipids and lipophilic active pharmaceutical ingredients (APIs). Lipids are small hydrophobic or amphipathic molecules, including fatty acids (such as omega-3 fatty acids and omega-6 fatty acids), steroids, hormones and fat-soluble vitamins (such as vitamins A, D, E and K).

The business model is to apply the ALT platform to lipids or lipophilic APIs to create unique product candidates that address the disorders and diseases that result from imbalances of lipids in the body. In addition to Sancilio’s primary focus of developing proprietary products using the ALT platform, the company makes use of and license rights to the proprietary ALT platform and other technologies to third parties as part of the development and manufacture of lipophilic API-based and soft-gelatin products at our facilities.

ALSO READ: 5 Big FDA Decisions Expected in September

According to the filing, Sancilio detailed its strategy as:

Our regulatory strategy is focused on seeking the most efficient pathway for obtaining drug approval while seeking the best available protections for our product candidates. To create our proprietary product candidates, we apply our ALT platform to a combination of lipophilic APIs, each of which is composed of active ingredients already approved by the FDA or active ingredients for which clinical proof of safety or efficacy is available in published literature. As a result, we believe that we are able to utilize the 505(b)(2) New Drug Application, or NDA, regulatory approval pathway.

The company intends to use the proceeds to develop its pipeline, as well as for general corporate purposes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.